美洛西林钠治疗卒中相关性肺炎的效果

Clinical effect of mezlocilin sodium on stroke-associated pneunmonia

目的分析关洛西林钠治疗卒中相关性肺炎的临床效果。方法选取卒中相关性肺炎患者142例，按随机数字表法分为观察组和对照组，均给予吸氧、化痰等基础治疗，对照组在常规治疗基础上再给予注射用头孢哌酮舒巴坦治疗，观察组在常规治疗基础上再给予注射用美洛西林钠治疗，治疗后观察治疗效果。结果治疗后两组患者中性粒细胞，白细胞计数（WBC）及超敏C-反应蛋白（hs-CRP）水平均有显著性下降（P〈0．05），但两组间比较差异未见统计学意义（P〉0．05）。治疗后观察组病原菌总清除率为89．2％，对照组病原菌总清除率为91．7％，两组比较差异未见统计学意义（χ^2=0．129，P〉0．05）。治疗后观察组显效、有效、无效及总有效率分别为36、32、3例及95．8％；对照组显效、有效、无效及总有效率分别为34、35、2例及97．2％，两组患者治疗总有效率比较差异未见统计学意义（χ^2=0．207，P〉0．05）。结论头孢哌酮舒巴坦和美洛西林钠治疗卒中相关性肺炎临床效果均满意，临床上可对这两种药物灵活选择，有效搭配，以达到最佳治疗效果。

Objective To analyze the clinical effect of mezlocilin sodium on stroke-associated pneunmonia. Methods The 142 patients with stroke-associated pneunmonia were selected and divided into observation group and control group. The patients all received basic and conventional treatment. And the control group and observation group also received cefoperazone sulbactam and mezloeilin sodium respectively. The clinical effects were observed after treatment. Results The levels of neutrophils, WBC and hs-CRP of the two groups after treatment were significantly lower than those before treatment（ P 〈0.05 ） , and these indexes between groups had no significant difference（P 〉0. 05 ）. The total clearance of original bacteria of observation group was 89.2% , which had no significant difference with that of control group （ χ^2 = 0. 129, P 〉 0. 05 ） , and the total efficiency of the treatment of observation group was 95.8% , which also had no significant difference with that of control group（ χ^2 = 0. 207, P 〉 0. 05 ）. Conclusions Mezlocilin sodium and cefoperazone sulbactam in the treatment of patients with stroke-associated pneunmonia are both effective.